Equity Overview
Price & Market Data
Price: $9.75
Daily Change: +$1.10 / 11.28%
Daily Range: $8.22 - $10.25
Market Cap: $22,717,842
Daily Volume: 135,005
Performance Metrics
1 Week: 67.28%
1 Month: 69.56%
3 Months: 15.39%
6 Months: 133.5%
1 Year: 254.3%
YTD: 92.84%
Company Details
Employees: 7
Sector: Health technology
Industry: Biotechnology
Country:
Details
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.